Lingvay, Ildiko

Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS ‐1 to ‐5 studies

Lingvay, I., Cheng, A. Y., Levine, J. A., Gomez‐Valderas, E., Allen, S. E., Ranta, K., Torcello‐Gómez, A., & Thieu, V. T. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 36

Safety profile of semaglutide versus placebo in the SELECT study: a randomized controlled trial

Kushner, R. F., Ryan, D. H., Deanfield, J., Kokkinos, A., Cercato, C., Wilding, J., Burguera, B., Wu, C., Craciun, A., Pall, D., et al. (2025) · Obesity

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 35

Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14

Pratley, R. E., Husain, M., Lingvay, I., Pieber, T. R., Mark, T., Saevereid, H. A., Møller, D. V., Zinman, B., & the DEVOTE Study Group (2019) · Cardiovascular Diabetology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 25

High-Dose Semaglutide (Up to 16 mg) in People With Type 2 Diabetes and Overweight or Obesity: A Randomized, Placebo-Controlled, Phase 2 Trial

Aroda, V. R., Jørgensen, N. B., Kumar, B., Lingvay, I., Laulund, A. S., Buse, J. B., & trial investigators (2025) · Diabetes Care

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 25

Occurrence of Gastrointestinal Adverse Events Upon GLP-1 Receptor Agonist Initiation With Concomitant Metformin Use: A Post Hoc Analysis of LEADER, STEP 2, SUSTAIN-6, and PIONEER 6

Klein, K. R., Clemmensen, K. K. B., Fong, E., Olsen, S., Abrahamsen, T., & Lingvay, I. (2024) · Diabetes Care

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 22

There is no magic bullet for obesity

Lingvay, I., Sumithran, P., le Roux, C. W., & Cohen, R. V. (2023) · The Lancet Diabetes & Endocrinology

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 16

Risk of Stroke in Real-World US Individuals with Type 2 Diabetes Receiving Semaglutide or a Dipeptidyl Peptidase 4 Inhibitor

Evans, M., Husain, M., Srivastava, A., Mangla, K. K., Kuhlman, A. B., & Lingvay, I. (2024) · Advances in Therapy

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 13

Thyrotropin-secreting adenoma in a patient with primary hypothyroidism

Myers, A., Hatanpaa, K. J., Madden, C., & Lingvay, I. (2011) · Endocrine Practice

Pituitary Gland Disorders and TreatmentsThyroid Disorders and Treatments

Cited by 13

Effects of once‐weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN‐6 trial

Kolkailah, A. A., Lingvay, I., Dobrecky‐Mery, I., Aharonovich, A., David, J., Holse, C., Rasmussen, S., & McGuire, D. K. (2023) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 6

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)

Rubino, D. M., Abrahamsson, N., Davies, M., Hesse, D., Greenway, F. L., Jensen, C., Lingvay, I., Mosenzon, O., Rosenstock, J., Rubio, M. A., et al. (2021) · Journal of the Endocrine Society

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 3

Semaglutide, inflammatory markers and cardiovascular outcomes in patients with overweight or obesity in the SELECT trial

Plutzky, J., Bogdański, P., Dagdelen, S., Deanfield, J., Emerson, S., Hovingh, G., Kahn, S., Larsen, S., Latkovskis, G., Lehrke, M., et al. (2024) · Atherosclerosis

Adipokines, Inflammation, and Metabolic DiseasesDiabetes Treatment and Management

Cited by 2